

**Supplementary Table 7.** Prevalence of *MET* tyrosine kinase domain (TKD) mutations among “other cancers” from Supplementary Table 6.

Cancer Type	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (N)	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (%)	<i>MET</i> TKD mutations of unknown biological function (N)	<i>MET</i> TKD mutations of unknown biological function (%)	Total <i>MET</i> TKD mutations (N)	Total <i>MET</i> TKD mutations (%)	Total (N)
Adenocarcinoma, NOS	1	0.09	1	0.09	2	0.17	1,160
Poorly Differentiated Carcinoma, NOS	0	0	2	0.46	2	0.46	436
Sellar Tumor, NOS	0	0	1	12.50	1	12.50	8
Squamous Cell Carcinoma, NOS	0	0	2	0.65	2	0.65	306
Chondroblastoma	0	0	1	33.33	1	33.33	3
Extramammary Paget Disease	0	0	1	16.67	1	16.67	6
Medulloblastoma	0	0	1	0.34	1	0.34	292
Papillary Thyroid Cancer	0	0	2	0.19	2	0.19	1,056
Yolk Sac Tumor	0	0	1	1.10	1	1.10	91
Germinoma	0	0	1	7.69	1	7.69	13
Adrenocortical Carcinoma	0	0	1	0.48	1	0.48	210
Granulosa Cell Tumor	0	0	1	0.72	1	0.72	139
Pleural Mesothelioma	0	0	2	0.28	2	0.28	712
Malignant Peripheral Nerve Sheath Tumor	0	0	1	0.69	1	0.69	145

Abbreviation: NOS: not otherwise specified.